^
Association details:
| Biomarker: | FGFR2-ARHGAP24 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | TT-00434 (FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Published date:
11/27/2023
Excerpt:
This phase 1, multicenter, open-label, dose-escalation study enrolled pts with advanced solid tumors who had exhausted all available standard treatments...One cholangiocarcinoma pt with FGFR alteration (FGFR2(17)-ARHGAP24(3) fusion) treated at 80 mg achieved partial response...This first-in-human study of TT-00434 showed a manageable and well-tolerated safety profile. The preliminary antitumor activity was observed in pt with FGFR2 altered cholangiocarcinoma.
Trial ID:
